Hefei Lifeon Pharmaceutical's application for the listing of neneftorone raw materials has been accepted.

date
11:48 10/02/2026
avatar
GMT Eight
Cubic Pharmaceutical (003020.SZ) announced that the company has received the "Acceptance Notice" for the application for the listing of spironolactone raw materials issued by the National Medical Products Administration. Spironolactone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA), and its formulation is used in adult patients with chronic kidney disease associated with type 2 diabetes, reducing the risk of continuous decline in eGFR and end-stage renal disease.
Hefei Lifeon Pharmaceutical (003020.SZ) announced that the company has received the "Acceptance Notice" for the application to list nefeidalone as an active pharmaceutical ingredient from the National Medical Products Administration. Nefeidalone is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA). Its formulation is used in adult patients with chronic kidney disease associated with type 2 diabetes, and can reduce the risk of continuous decline in eGFR and end-stage renal disease.